Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Transplantation and Cellular Therapy|May 24, 2023
Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell TherapyJames A Davis, Douglas W Sborov, William Wesson, et al.
Cytotherapy|December 10, 2025
A phase 1b study on the safety of Wharton's jelly mesenchymal stromal cells in the treatment of acute graft-versus-host diseaseWilliam Wesson, Jianzheng Wu, Milind Phadnis, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2022
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic reviewWilliam Wesson, Vincent L Galate, Douglas W Sborov, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 29, 2025
Dosimetry Assessment in Predicting Treatment Outcomes Following Yttrium-90 Transarterial Radioembolization of Hepatic TumorsChristina Ward, Sandon Scott, William Wesson, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2024
The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and MyelomaAroog Khaliq, William Wesson, Emerson Logan, et al.
European Journal of Haematology|December 4, 2023
Safety and efficacy of eltrombopag in patients with post-CAR T cytopeniasWilliam Wesson, Nausheen Ahmed, Aliya Rashid, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple MyelomaAliya Rashid, William Wesson, Al-Ola Abdallah, et al.
Journal of Hematology|January 8, 2024
Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World ExperienceAswani Thurlapati, William Wesson, James A Davis, et al.
Frontiers in Oncology|August 21, 2023
"Waitlist mortality" is high for myeloma patients with limited access to BCMA therapyNausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
Pageof 2